KRYS Stock Analysis: Buy, Sell, or Hold?
KRYS - Krystal Biotech, Inc. Common Stock
$279.24
-0.10 (-0.04%)
▼
5d:
-0.81%
30d:
+12.65%
90d:
+50.9%
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 18, 2026
15d
Get Alerted When KRYS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: KRYS shows positive signals but monitor for confirmation. Market pricing in 3.8% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: KRYS shows positive signals but monitor for confirmation. Market pricing in 3.8% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$386.94
Based on 13.2% avg growth
INTRINSIC VALUE TODAY
$240.26
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: KRYS is currently trading at $279.24, which is considered slightly high relative to its 30-day fair value range of $250.92 to $284.30. From a valuation perspective, the stock is trading at a premium (Forward PE: 33.3) compared to its historical average (29.8). At these levels, the market is pricing in 3.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, KRYS is in a strong uptrend. The price is currently testing key support at $271.52. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KRYS is in a strong uptrend. The price is currently testing key support at $271.52. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$250.92 -
$284.30
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.8%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($276.60)
- NEUTRAL: Market pricing in 3.8% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$250.92 -
$284.30
Current vs Fair Value
SLIGHTLY HIGH
Expected Move (7 Days)
±$18.71
(6.7%)
Support & Resistance Levels
Support Level
$271.52
Resistance Level
$294.64
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
33.26
Wall Street Target
$276.60
(-0.9%)
Revenue Growth (YoY)
16.6%
Earnings Growth (YoY)
192.3%
Profit Margin
53.3%
Valuation Premium vs History
+3.8% premium
PE vs Historical
33.3 vs 29.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.8%
(market-implied from PE analysis)
1-Year Target
$289.85
(+4%)
2-Year Target
$300.87
(+8%)
3-Year Target
$312.30
(+12%)
3-Yr Target (if PE normalizes)
(PE: 33→30)
PE COMPRESSION
$279.82
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 33.3, Growth: 22.4%)
$511.94
(+83%)
Base:
(SPY PE: 22.3, Growth: 22.4%)
$343.26
(+23%)
Bear:
(PE: 19.0, Growth: 22.4%)
$291.77
(+5%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (41x PE), but valuation improves significantly next year (33x PE) as earnings recover.
Trailing PE: 40.85 | Current EPS (TTM): $6.68
Bull Case
$379.48
(+36%)
Analyst growth 26.4%, PE expands to 44.9
Base Case
$344.98
(+24%)
Market implied 26.4%, PE stable at 40.9
Bear Case
$185.58
(-34%)
Severe decline -20.0%, PE contracts to 34.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: February 01, 2026 11:20 PM ET
Data refreshes hourly during market hours. Next update: 12:20 AM
Data refreshes hourly during market hours. Next update: 12:20 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KRYS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$66 | 46 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$112 | 52 HOLD |
|
RNA
Avidity Biosciences Inc |
STRONG BUY
15 analysts |
$75 | 62 BUY |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$108 | 56 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$34 | 51 HOLD |
Advanced KRYS Option Strategies
Professional options setups generated by AI based on today's KRYS price and gamma walls.
